2024
Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates
Thiam L, McHugh K, Ba A, Li R, Guo Y, Pouye M, Cisse A, Pipini D, Diallo F, Sene S, Patel S, Thiam A, Sadio B, Mbengue A, Vigan-Womas I, Sheng Z, Shapiro L, Draper S, Bei A. Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates. Npj Vaccines 2024, 9: 198. PMID: 39448626, PMCID: PMC11502735, DOI: 10.1038/s41541-024-00986-x.Peer-Reviewed Original ResearchP. falciparum clinical isolatesClinical isolatesNext-generation sequencingEarly clinical studiesDose-dependent inhibitionGrowth inhibition activitySingle B cellsOccurrence of novel mutationsNext-generation sequencing analysisBlood-stageNo significant differencePfRH5MAb combinationsNovel mutationsClinical studiesNeutralizing activityAntibody susceptibilityIgG responsesPre-clinicalGenotype/phenotype relationshipsMonoclonal antibodiesVaccine alleleGenetic diversitySignificant differenceMAb
2022
Structure-guided insights into potential function of novel genetic variants in the malaria vaccine candidate PfRh5
Mangou K, Moore A, Thiam L, Ba A, Orfanó A, Desamours I, Ndegwa D, Goodwin J, Guo Y, Sheng Z, Patel S, Diallo F, Sene S, Pouye M, Faye A, Thiam A, Nunez V, Diagne C, Sadio B, Shapiro L, Faye O, Mbengue A, Bei A. Structure-guided insights into potential function of novel genetic variants in the malaria vaccine candidate PfRh5. Scientific Reports 2022, 12: 19403. PMID: 36371450, PMCID: PMC9653458, DOI: 10.1038/s41598-022-23929-9.Peer-Reviewed Original ResearchConceptsImmune evasionSingle nucleotide polymorphismsPopulation prevalenceVaccine-induced protective immunityP. falciparum positive samplesFalciparum positive samplesPlasmodium falciparum antigensMalaria vaccine candidateNovel single nucleotide polymorphismsInhibitory monoclonal antibodiesProtective immunityFalciparum antigensMalaria deathsEffective vaccineEfficacious vaccineVaccine candidatesPfRH5Infected individualsVaccine targetsMonoclonal antibodiesLow overall frequencyReceptor bindingNovel genetic variantsVaccineOverall frequency